版本:
中国

BRIEF-Oncolytics Biotech announces registration pathway and clinical development plan

April 12 Oncolytics Biotech Inc -

* Announces registration pathway and clinical development plan

* Announced initial registration pathway and clinical development plan for reolysin, proprietary immuno-oncology viral agent

* Trial will recruit approximately 44 patients across up to six myeloma UK clinical trial network centres in UK

* Oncolytics and Celgene UK & Ireland are providing respective products for muk eleven

* Oncolytics is providing Reolysin and Celgene UK & Ireland is providing imnovid and revlimid Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐